These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 32603829)

  • 21. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.
    Yang N; Shen HM
    Int J Biol Sci; 2020; 16(10):1724-1731. PubMed ID: 32226290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
    He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W
    Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Characteristics of SARS-CoV-2 and potential pharmacological treatment].
    Pawlik L; Śpiołek E; Fichna J; Tarasiuk A
    Postepy Biochem; 2020 May; 66(2):83-90. PubMed ID: 32700510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 from the Perspective of a Gastroenterologist.
    Boo SJ
    Korean J Gastroenterol; 2020 Jul; 76(1):4-8. PubMed ID: 32703914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of lethal human coronaviruses.
    Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
    Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 and COVID-19: From the Bench to the Bedside.
    Romagnoli S; Peris A; De Gaudio AR; Geppetti P
    Physiol Rev; 2020 Oct; 100(4):1455-1466. PubMed ID: 32496872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coronavirus disease 2019: a clinical review.
    Yang CL; Qiu X; Zeng YK; Jiang M; Fan HR; Zhang ZM
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4585-4596. PubMed ID: 32373999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients.
    Yashavantha Rao HC; Jayabaskaran C
    J Med Virol; 2020 Jul; 92(7):786-790. PubMed ID: 32320066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
    Ye ZW; Jin DY
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.
    Lin L; Lu L; Cao W; Li T
    Emerg Microbes Infect; 2020 Dec; 9(1):727-732. PubMed ID: 32196410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2.
    Ling R; Dai Y; Huang B; Huang W; Yu J; Lu X; Jiang Y
    Peptides; 2020 Aug; 130():170328. PubMed ID: 32380200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
    Krishna G; Pillai VS; Veettil MV
    Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on novel COVID-19 pandemic: a battle between humans and virus.
    Prajapati S; Sharma M; Kumar A; Gupta P; Narasimha Kumar GV
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5819-5829. PubMed ID: 32495921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding COVID-19: From Origin to Potential Therapeutics.
    Moazzam M; Sajid MI; Shahid H; Butt J; Bashir I; Jamshaid M; Shirazi AN; Tiwari RK
    Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32823901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
    Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
    Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview: The history and pediatric perspectives of severe acute respiratory syndromes: Novel or just like SARS.
    Hon KL; Leung KKY; Leung AKC; Sridhar S; Qian S; Lee SL; Colin AA
    Pediatr Pulmonol; 2020 Jul; 55(7):1584-1591. PubMed ID: 32483934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
    Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
    J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.